FAQ

NCX1000

Known as: NCX 1000, NCX-1000 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2009
012320012009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… (More)
  • table 1
  • figure 2
  • table 2
  • figure 1
  • table 3
Is this relevant?
2009
2009
Notice of Retraction: 'Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice' (Br J Pharmacol 143; 33-42; 2004).
  • British journal of pharmacology
  • 2009
 
Is this relevant?
2007
2007
Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… (More)
Is this relevant?
2004
2004
Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice.
1. NCX-1000, (3alpha, 5beta, 7beta)-3,7-dihydroxycholan-24oic acid[2-methoxy-4-[3-[4-(nitroxy)butoxy]-3-oxo-1-propenyl]phenyl… (More)
Is this relevant?
Review
2004
Review
2004
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… (More)
Is this relevant?
2003
2003
A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
BACKGROUND/AIMS A decreased intra-hepatic nitric oxide (NO) production participates on the pathogenesis of portal hypertension in… (More)
Is this relevant?
2003
2003
NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver…
BACKGROUND/AIMS We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic… (More)
Is this relevant?
2003
2003
Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver.
Portal hypertension, a common consequence of chronic liver diseases, is directly responsible for most complications of cirrhosis… (More)
Is this relevant?
2001
2001
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… (More)
Is this relevant?
2001
2001
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity.
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?